Coming Soon! March 2021
VIRALEZE™ Antiviral Nasal Spray
Shown in laboratory studies to inactivate a broad spectrum of respiratory viruses, including >99.9% of coronavirus SARS-CoV-2, the virus that causes COVID-19
Product is expected to be available March 2021. Sign Up for updates.
What is VIRALEZE™ Anitiviral Nasal Spray?
VIRALEZE™ is an antiviral nasal spray that contains astodrimer sodium (SPL7013), which has been shown in laboratory studies to inactivate a broad spectrum of respiratory viruses, including >99.9% of coronavirus SARS-CoV-2, the virus that causes COVID-19.
The nasal cavity is the primary site where SARS-CoV-2 (COVID-19) becomes established, before spreading to the lungs^.
^Hou et al., 2020, Cell 182, 429–446
How does VIRALEZE™ work?
VIRALEZE™ is an easy to use antiviral nasal spray, which can be stored at room temperature and does not require refrigeration.
VIRALEZE™ contains astodrimer sodium, which has been shown in laboratory studies to inactivate viruses, including SARS-CoV-2, influenza and respiratory syncytial virus (RSV).
“Spike” proteins on the surface of these viruses that come into contact with VIRALEZE™ are trapped by astodrimer sodium. This interaction is ‘virucidal’ – the virus is irreversibly blocked and can no longer infect mucosal cells, thereby providing a physical barrier to respiratory viruses in the nasal cavity. These “blocked” viruses are then eliminated naturally through the nasal mucus.
While providing a barrier to viruses, VIRALEZE™ also provides a moisture layer to help keep nasal tissue hydrated, protecting from dryness and damage.
VIRALEZE™ can be used with vaccination, personal protective equipment (PPE) and good hygiene practices, along with physical distancing.
Please always follow your local health and medical advice to ensure the best possible protection against respiratory viruses, which may include vaccination, personal protective equipment (PPE) and good hygiene practices, along with physical distancing.
VIRALEZE™ can also be used as required, up to 4 times a day. Please refer to the Instructions for Use leaflet before using VIRALEZE™ ANTIVIRAL NASAL SPRAY. Seek medical advice if you have respiratory symptoms. Adult use only. Keep out of reach of children.
VIRALEZE™ developed in Australia by Starpharma
Astodrimer sodium (also known as SPL7013) is a patented, precisely designed large molecule that acts locally at site of application with no systemic absorption, meaning it does not enter the bloodstream.
Astodrimer sodium is included in products licensed in >160 countries, approved in >40 countries and available for sale in the UK, Europe, South East Asia, Australia and New Zealand.
Starpharma is a world leader in the development of new medical products based on its proprietary dendrimer technology and has partnerships with leading global companies, including AstraZeneca, MSD (Merck & Co., Inc.,), Okamoto, LifeStyles, Aspen and Mundipharma. Starpharma is listed on the Australian stock exchange (ASX:SPL).
Starpharma was awarded development funding for VIRALEZE™ by the Australian Government’s Medical Research Future Fund Biomedical Translation Bridge Program.